scholarly journals 207 Cancer testis antigen melanoma-associated antigen A3 (MAGE-A3) promotes cutaneous squamous cell carcinoma growth in vivo

2018 ◽  
Vol 138 (5) ◽  
pp. S35
Author(s):  
A. Santana ◽  
N. Roudiani ◽  
K. Laursen ◽  
D. Felsen ◽  
J.A. Carucci
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Cancer Testis Antigen ◽  
Cancer Testis

scholarly journals A Unique Panel of Patient-Derived Cutaneous Squamous Cell Carcinoma Cell Lines Provides a Preclinical Pathway for Therapeutic Testing

2019 ◽  
Vol 20 (14) ◽  
pp. 3428 ◽  
Author(s):  
Sakinah Hassan ◽  
Karin J. Purdie ◽  
Jun Wang ◽  
Catherine A. Harwood ◽  
Charlotte M. Proby ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cell Lines ◽  
Squamous Cell ◽  
Drug Screening ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Model Systems ◽  
Screening Methods

Background: Cutaneous squamous cell carcinoma (cSCC) incidence continues to rise with increasing morbidity and mortality, with limited treatment options for advanced disease. Future improvements in targeted therapy will rely on advances in genomic/transcriptomic understanding and the use of model systems for basic research. We describe here the panel of 16 primary and metastatic cSCC cell lines developed and characterised over the past three decades in our laboratory in order to provide such a resource for future preclinical research and drug screening. Methods: Primary keratinocytes were isolated from cSCC tumours and metastases, and cell lines were established. These were characterised using short tandem repeat (STR) profiling and genotyped by whole exome sequencing. Multiple in vitro assays were performed to document their morphology, growth characteristics, migration and invasion characteristics, and in vivo xenograft growth. Results: STR profiles of the cSCC lines allow the confirmation of their unique identity. Phylogenetic trees derived from exome sequence analysis of the matched primary and metastatic lines provide insight into the genetic basis of disease progression. The results of in vivo and in vitro analyses allow researchers to select suitable cell lines for specific experimentation. Conclusions: There are few well-characterised cSCC lines available for widespread preclinical experimentation and drug screening. The described cSCC cell line panel provides a critical tool for in vitro and in vivo experimentation.

Clinicopathological roles of S100A8 and S100A9 in cutaneous squamous cell carcinoma in vivo and in vitro

2014 ◽  
Vol 306 (5) ◽  
pp. 489-496 ◽  
Author(s):  
Dae-Kyoung Choi ◽  
Zheng Jun Li ◽  
In-Kyu Chang ◽  
Min-Kyung Yeo ◽  
Jin-Man Kim ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cutaneous Squamous Cell Carcinoma

scholarly journals Targeting COX-2 potently inhibits proliferation of cancer cells in vivo but not in vitro in cutaneous squamous cell carcinoma

2021 ◽  
Vol 10 (5) ◽  
pp. 2219-2228
Author(s):  
Lipeng Gao ◽  
Tim Hua Wang ◽  
Champ Peng Chen ◽  
Jan Jian Xiang ◽  
Xu-Bo Zhao ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Cells ◽  
Squamous Cell ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Cox 2

scholarly journals Transposon mutagenesis identifies cooperating genetic drivers during keratinocyte transformation and cutaneous squamous cell carcinoma progression

PLoS Genetics ◽  
2021 ◽  
Vol 17 (8) ◽  
pp. e1009094
Author(s):  
Aziz Aiderus ◽  
Justin Y. Newberg ◽  
Liliana Guzman-Rojas ◽  
Ana M. Contreras-Sandoval ◽  
Amanda L. Meshey ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cellular Transformation ◽  
Sleeping Beauty ◽  
Transposon Mutagenesis ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Genetic Landscape ◽  
Molecular Landscape

The systematic identification of genetic events driving cellular transformation and tumor progression in the absence of a highly recurrent oncogenic driver mutation is a challenge in cutaneous oncology. In cutaneous squamous cell carcinoma (cuSCC), the high UV-induced mutational burden poses a hurdle to achieve a complete molecular landscape of this disease. Here, we utilized the Sleeping Beauty transposon mutagenesis system to statistically define drivers of keratinocyte transformation and cuSCC progression in vivo in the absence of UV-IR, and identified both known tumor suppressor genes and novel oncogenic drivers of cuSCC. Functional analysis confirms an oncogenic role for the ZMIZ genes, and tumor suppressive roles for KMT2C, CREBBP and NCOA2, in the initiation or progression of human cuSCC. Taken together, our in vivo screen demonstrates an extremely heterogeneous genetic landscape of cuSCC initiation and progression, which can be harnessed to better understand skin oncogenic etiology and prioritize therapeutic candidates.

scholarly journals Plasma Treatment Limits Cutaneous Squamous Cell Carcinoma Development In Vitro and In Vivo

Cancers ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1993 ◽  
Author(s):  
Gabriella Pasqual-Melo ◽  
Thiago Nascimento ◽  
Larissa Juliani Sanches ◽  
Fernanda Paschoal Blegniski ◽  
Julya Karen Bianchi ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Plasma Treatment ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Healthcare Services ◽  
Skin Lesions ◽  
Cutaneous Squamous Cell Carcinoma ◽  
High Rate

Cutaneous squamous cell carcinoma (SCC) is the most prevalent cancer worldwide, increasing the cost of healthcare services and with a high rate of morbidity. Its etiology is linked to chronic ultraviolet (UV) exposure that leads to malignant transformation of keratinocytes. Invasive growth and metastasis are severe consequences of this process. Therapy-resistant and highly aggressive SCC is frequently fatal, exemplifying the need for novel treatment strategies. Cold physical plasma is a partially ionized gas, expelling therapeutic doses of reactive oxygen and nitrogen species that were investigated for their anticancer capacity against SCC in vitro and SCC-like lesions in vivo. Using the kINPen argon plasma jet, a selective growth-reducing action of plasma treatment was identified in two SCC cell lines in 2D and 3D cultures. In vivo, plasma treatment limited the progression of UVB-induced SSC-like skin lesions and dermal degeneration without compromising lesional or non-lesional skin. In lesional tissue, this was associated with a decrease in cell proliferation and the antioxidant transcription factor Nrf2 following plasma treatment, while catalase expression was increased. Analysis of skin adjacent to the lesions and determination of global antioxidant parameters confirmed the local but not systemic action of the plasma anticancer therapy in vivo.

Sign in / Sign up

Export Citation Format

Share Document